Non-analgesic effects of opioids: Opioids and the endocrine system

Current Pharmaceutical Design

Volumn 18, Issue 37, 2012, Pages 6070-6078

  Elliott, Jennifer A ^a   Opper, Susan E ^a   Agarwal, Sonali ^a   Fibuch, Eugene E ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Androgens; Depression; Endocrine; Hyperalgesia; Hypogonadism; Opioids; Osteoporosis; Testosterone

Indexed keywords

4 AMINOBUTYRIC ACID; ANDROGEN; ESTRADIOL; ESTRATEST; FOLLITROPIN; GLUTAMINE; LUTEINIZING HORMONE; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID; NALOXONE; OPIATE; PRASTERONE SULFATE; TESTOPEL; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; UNCLASSIFIED DRUG;

ADRENAL DISEASE; CHRONIC PAIN; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG POTENCY; DRUG SCREENING; DRUG USE; ENDOCRINE DISEASE; ERECTILE DYSFUNCTION; FIBROMYALGIA; HAMILTON SCALE; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPERALGESIA; HYPOGONADISM; HYPOTHALAMIC PITUITARY GONADAL AXIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LACTATION; LIBIDO; MENSTRUATION DISORDER; MOOD DISORDER; NOCICEPTION; NONHUMAN; OPIOID ASSOCIATED ENDOCRINOPATHY; OSTEOPOROSIS; PAIN ASSESSMENT; PRIORITY JOURNAL; REVIEW; TEMPOROMANDIBULAR JOINT DISORDER; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

ANALGESICS, OPIOID; ANIMALS; ENDOCRINE SYSTEM; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; HYPERALGESIA; HYPOGONADISM; MALE; PAIN; PAIN THRESHOLD; RISK FACTORS;

EID: 84873527513     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803582414     Document Type: Review

References (107)

1. Colamenco C, Coren JS. Opioid-induced endocrinopathy. J Am Osteopath Assoc 2009; 109(1): 20-5.
2. Katz N. The impact of opioids on the endocrine system. Pain Manage Rounds 2005; 1(9).
3. Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain 2009; 25(2): 170-5.
4. Merck Manual Professional. Male Hypogonadism: Male Endocrinology. [cited 2011 May 30]. Available at www.merck.com/mmpe/sec17/ch227/ch227b.html.
5. Snyder PJ. Causes of secondary hypogonadism in males. In: Martin KA, Eds.: Up to Date. Waltham, MA: Up to Date, 2011.
6. Finch PM, Roberts LJ, Price LS, et al. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain 2000; 16(3): 251-4.
7. Paice JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manage 1994; 9(2): 126-31.
8. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000; 85(6): 2215-22.
9. Roberts LJ, Finch PM, Goucke CR, et al. Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain 2001; 5: 353-61.
10. Bolelli G, lafisca S, Flamigni C, et al. Heroin addiction: Relationship between the plasma levels of testosterone, Dihydrotestosterone, androstenedione, LH, FSH, and the plasma concentration of heroin. Toxicology 1979; 15: 19-29.
11. Daniell HW. Narcotic-induced hypogonadism during therapy for heroin addiction. J Addict Dis 2002; 21(4): 47-53.
12. Fraser L-A, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain: Higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes 2009; 117: 38-43.
13. Rajogopal A, Vassilopoulou-Sellin R, Palmer JL, et al. Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy J Pain Symptom Manage. 2003; 26(5): 1055-61.
14. Rajogopal A, Vassilopoulou-Sellin R, Palmer JL, et al. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004; 100(4): 851-8.
15. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002; 3(5): 377-84.
16. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain 2008; 9(1): 28-36.
17. Roberts LJ, Finch PM, Pullan PT, Bhagat CI, Price LM. Sex hormone suppression by intrathecal opioids: A prospective study. Clin J Pain 2002; 18: 144-8.
18. Miller KK, Sesmilo G, Schiller A, et al. Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab 2001; 86(2): 561-7.
19. Bachmann G, Oza D. Female androgen insufficiency. Obstet Gynecol North Am 2006; 33: 589-8.
20. Daniell HW. DHEAS deficiency during consumption of sustainedaction prescribed opioids: Evidence for opioid-induced inhibition of adrenal androgen production. J Pain 2006; 7(12): 901-907.
21. Davis S. Testosterone deficiency in women. J Reprod Med 2001; 46(3): 291-6.
22. Finkelstein JS: Epidemiology and etiology of osteoporosis in men. In: Mulder JE Ed.: Up To Date. Waltham, MA: Up To Date, 2011.
23. Seeman E, Melton LJ III, O'Fallon WM, Riggs BL. Risk factors for spinal osteoporosis in men. Am J Med 1983; 75: 977.
24. Kim TW, Alford DP, Malabanan A, et al. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 2006; 85: 258-62.
25. Kelepuris N, Harper KD, Gannon F, et al. Severe osteoporosis in men. Ann Intern Med 1995; 123: 452.
26. Daniell HW. Opioid-induced androgen deficiency. Curr Opin Endocrinol Diabetes 2006; 13: 262-6.
27. Fortin JD, Bailey GM, Vilensky JA. Does opioid use for pain management warrant routine bone mass density screening in men? Pain Physician 2008; 11: 539-41.
28. Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 2006; 91: 3908-15.
29. Daniell HW. Opioid osteoporosis. Arch Intern Med. 2164:338.004;
30. Reddy RG, Aung T, Karavitaki N, Wass JA. Opioid induced hypogonadism. BMJ 2010; 341: 605-6.
31. Schneider J. Hypogonadism in men treated with chronic opioids. Arch Phys Med Rehabil 2008; 89: 1414 (Letter).
32. Zarrouf FA, Artz S, Griffith J, et al. Testosterone and depression: Systematic review and meta-analysis. J Psychiatr Pract 2009. 15: 289-305.
33. Pope HG, Cohane GH, Kanamaya G, et al. Testosterone gel supplementation for men with refractory depression: A randomized, placebo-controlled trial. Am J Psychiatry 2003. 160: 105-11.
34. Bair MJ, Robinson R, Katon W, Kroenke K. Depression and pain comorbidity: A literature review. Arch Intern Med 2003; 163: 2433-45.
35. Kennedy SE, Koeppe RA, Young EA, Zubieta J-K. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006; 63: 1199-208.
36. Fitzgerald P, Dinan TG. Prolactin and dopamine: What is the connection? A review article. J Psychopharmacol 2008; 22(2): 12-9.
37. Vuong C, Van Uum SHM, O'Dell LE, et al. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocrine Rev 2010; 31(1): 98-132.
38. Moshtaghi-Kashanian GR, Esmaeeli F, Dabiri S. Enhanced prolactin levels in opium smokers. Addict Biol 2005; 10: 325-49.
39. Rhodin A, Stridsberg M., Gordh T. Opioid endocrinopathy: A clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 2010; 26(5): 374-80.
40. Willoughby JO, Medvedev A. Opioid receptor activation resets the hypothalamic clock generating growth hormone secretory bursts in the rat. J Endocrinol 1996; 148: 149-55.
41. Janik J, Klosterman S, Purman R, Callahan P. Multiple opiate receptor subtypes are involved in the stimulation of growth hormone release by α-endorphin in female rats. Neuroendocrinology 1994; 60: 69-75.
42. Barbarino A, De Marinis L, Manchi A, et al. Sex-related naloxone influence on growth hormone-releasing hormone-induced growth hormone secretion in normal subjects. Metabolism 1987; 36: 105-9.
43. Henrohn D, Le Greves P, Nyberg F. Morphine alters the levels of growth hormone receptor mRNA and [125I] growth hormone binding in human IM-9 lymphoblasts via a naloxone-reversible mechanism. Mol Cell Endocrinol 1997; 135: 147-52.
44. Allolio B, Schulte HM, Deuss U, et al. Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotrophin-releasing hormone. Acta Endocrinol 1987; 114: 509-14.
45. Cole, BE. Neuroendocrine implications of opioid therapy. Curr Pain Headache Rep 2007; 11: 89-92.
46. Aloisi AM, Aurillo C, Bachiocco V, et al. Endocrine consequences of opioid therapy. Psychoneuroendocrinology 2009; 34S: S162-8.
47. Grossman A, Moult PJ, Cunnah D, Besser M. Different opioid mechanisms are involved in the modulation of ACTH and gonadotropin release in man. Neuroendocrinology 1986; 42: 357-60.
48. Pfeiffer A, Knepel W, Braun S, et al. Effects of a δ-opioid agonist on adrenocorticotropic and diuretic function in man. Horm Metab Res 1986: 18(12): 842-8.
49. Merza Z. Chronic use of opioids and the endocrine system. Horm Metab Res 2010; 42: 621-6.
50. DuPen A, Shen D, Ersek M. Mechanisms of opioid-induced tolerance and hyperalgesia. Pain Manag Nurs 2007; 8(3): 113-21.
51. Angst MS, Clark JD. Opioid-induced hyperalgesia: A qualitative systematic review. Anesthesiology 2006; 104: 570-87.
52. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008; 11: S105-20.
53. Silverman SM. Opioid induced hyperalgesia: Clinical implications for the pain practitioner. Pain Physician 2009; 12: 679-84.
54. Albutt C. On the abuse of hypodermic injections of morphia. Practitioner 1870; 5: 327-31.
55. Fishbain DA, Cole B, Lewis JE, et al. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 2009; 10(5): 829-39.
56. Lee M, Silverman S, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14: 145-61.
57. Lotsch J. Opioid metabolites. J Pain Symptom Manage 2005; 29: S10-25.
58. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality. Part II. Psychosomatics 2003; 44: 515-20.
59. Wright AW, Nocente ML, Smith MT. Hydromorphone-3-gulcuronide: Biosynthesis and preliminary pharmacological evaluation. Life 1998; 63: 401-11.
60. Mao J. Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain 2002; 100: 213-17.
61. Celerier E, Rivat C, Jun Y, et al. Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effects of ketamine. Anesthesiology 2000; 92: 465-72.
62. Van Elstraete AC, Sitbon P, Trabold F, et al. A single dose of intrathecal morphine in rats induces long-lasting hyperalgesia: The protective effect of prior administration of ketamine. Anesth Analg 2005; 101: 1750-6.
63. Compton P, Charuvastra VC, Ling w. Pin intolerance in opioidmaintained former opiate addicts: Effect of long-acting maintenance agent. Drug Alcohol Depend 2001; 63: 139-46.
64. Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000; 93: 409-17.
65. Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high dose opioids. J Opioid Manage 2006; 2(5); 277-82.
66. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: A preliminary prospective study. J Pain 2006; 7: 43-8.
67. Hay JL, White JM, Bochner F, et al. Hyperalgesia in opioidmanaged chronic pain and opioid-dependent patients. J Pain 2009; 10: 316-22.
68. Bannister K, Dickenson AH. Opioid hyperalgesia. Curr Opin Support Palliat Care 2010; 4: 1-5.
69. Mitra S. Opioid-induced hyperalgesia: Pathophysiology and clinical implications. J Opioid Manage 2008; 4: 123-30.
70. Cohen SP, Christo PJ, Wang S, et al. The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg Anesth Pain Med 2008; 33: 199-206.
71. Angst MS, Koppert W, Pahl I, et al. Short-term infusion of the muopioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 2003; 106: 49-57.
72. Koppert W, Sittl R, Scheuber K, et al. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by Sketamine and clonidine in humans. Anesthesiology 2003; 99: 152-9.
73. Quartilho A, Mata HP, Ibrahim MM, et al. Production of paradoxical sensory hypersensitivity by alpha-2-adrenoceptor agonists. Anesthesiology 2004; 100: 1538-44.
74. Davies MF, Haimor F, Lighthall G, Clark JD. Dexmedetomidine fails to cause hyperalgesia after cessation of chronic administration. Anesth Analg 2003; 96: 195-200.
75. Hood DD, Curry R, Eisenach JC. Intravenous remifenatnil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. Anesth Analg 2003; 97: 810-5.
76. Reznikov I, Pud D, Eisenberg E. Oral opioid administration and hyperalgesia in patients with cancer or chronic nonmalignant pain. Br J Clin Pharmacol 2005; 60: 311-8.
77. Mao L, Sung B, Ji RR, Lim G. Neuronal apoptosis associated with morphine tolerance: Evidence for an opioid-induced neurotoxic mechanism. J Neurosci 2002; 22: 7650-61.
78. Mercadante S, Ferrera P, Villari P, Arcuri E. Hyperalgesia: An emerging iatrogenic syndrome. J Pain Symptom Manage 2003; 26: 769-75.
79. Chu LF, Dairmont J, Zamora AK, et al. The endogenous opioid system is not involved in modulation of opioid-induced hyperalgesia. J Pain 2011; 12(1): 108-15.
80. Morgan MM, Heinricher MM, Fields HL. Circuitry linking opioidsensitive nociceptive modulatory systems in periaqueductal gray and spinal cord with rostral ventromedial medulla. Neuroscience 1992; 47: 863-71.
81. Heinricher MM, Morgan MM, Fields HL. Direct and indirect actions of morphine on medullary neurons that modulate nociception. Neuroscience 1992; 48: 533-43.
82. Liang DY, Liao G, Wang J, et al. A genetic analysis of opioidinduced hyperalgesia in mice. Anesthesiology 2006; 104:1054-62.
83. Li X, Clark JD. Hyperalgesia during opioid abstinence: Mediation by glutamine and substance P. Anesth Analg 2002; 95: 979-84.
84. Zhao M, Daisy T, Joo MD. Enhancement of spinal N-Methyl-DAspartate receptor function by remifentanil action at δ-opioid receptors as a mechanism for acute opioid-induced hyperalgesia or tolerance. Anesthesiology 2008; 109: 308-17.
85. Dessein PH, Shipton EA, Stanwix AE, Joffe BI. Neuroendocrine deficiency-mediated development and persistence of pain in fibromyalgia: A promising paradigm? Pain 2000; 86: 213-5.
86. Craft RM, Mogil JS, Aloisi AM. Sex differences in pain and analgesia: the role of gonadal hormones. Eur J Pain 2004; 8: 397-411.
87. Craft RM. Modulation of pain by estrogens. Pain 2007; 132: S3-12.
88. Ceccarelli I, De Padova AM, Fiorenzani P, et al. Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats. Neuroscience 2006; 140: 929-37.
89. Stoffel EC, Ulibarri CM, Craft RM. Gonadal steroid hormone modulation of nociception, morphine antinociception, and reproductive indices in male and female rats. Pain 2003; 103: 285-302.
90. Aloisi AM, Ceccarelli I, Fiorenzani P. Gonadectomy affects hormonal and behavioral responses to repetitive nociceptive stimulation in male rats. Ann NY Acad Sci 2003; 1007: 232-7.
91. Bachmann G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: The Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77(4): 660-5.
92. Arlt W: Androgen therapy in women. Eur J Endocrinol 2006; 154: 1-11.
93. Daniell HW. Opioid-induced androgen deficiency discussion in opioid contracts. Am J Med 2007; 120: e21 (Letter).
94. Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006; 91(10): 3697-710.
95. Miller KK. Androgen deficiency in women. J Clin Endocrinol Metab 2001; 86(6): 2395-401 (Commentary).
96. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010; 95(6): 2536-59.
97. Endocrinologist's Guidelines for the Diagnosis and Treatment of Menopause: Androgen deficiency in postmenopausal women. [cited 9 July 2011] Available at www.medscape.com/viewarticle/540531_12.
98. Fernandez-Balssells MM, Murad MH, Lane M, et al. Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-75.
99. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363(2): 109-22.
100. Amin S, Zhang Y, Felson DT, et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med 2006; 119: 426-33.
101. Elliott JA, Horton E, Fibuch EE. The endocrine effects of long-term oral opioid therapy: A case report and review of the literature. J Opioid Manage 2011; 7(2): 145-54.
102. Auernhammer CJ, Vlotides G. Anterior pituitary hormone replacement therapy: A clinical review. Pituitary 2007; 10: 1-15.
103. Snyder PJ. Testosterone treatment of male hypogonadism. In: Marin KA Ed.: Up To Date. Waltham, MA: Up To Date, 2011.
104. Lexi-Comp Online: Testosterone. Lexi-Drugs Online. Lexi-Comp, Inc., 1978-2011. Available at www.lexi.com.
105. Davis S. Androgen replacement in women: A commentary. J Clin Endocrinol Metab 1999; 84: 1866-91.
106. Mazer NA. Testosterone deficiency in women: Etiologies, diagnosis, and emerging treatments. Int J Fertil 2002; 47(2): 77-86.
107. Tennant F. Testosterone replacement in female chronic pain patients. Pract Pain Manage 2009;: 25-7.